Diagnosing and treating hypersomnolence in depression.

Circadian rhythms Excessive daytime sleepiness Hypersomnolence Pharmacotherapy Sleep

Journal

Sleep medicine
ISSN: 1878-5506
Titre abrégé: Sleep Med
Pays: Netherlands
ID NLM: 100898759

Informations de publication

Date de publication:
10 Oct 2024
Historique:
received: 25 08 2024
revised: 02 10 2024
accepted: 08 10 2024
medline: 19 10 2024
pubmed: 19 10 2024
entrez: 18 10 2024
Statut: aheadofprint

Résumé

Hypersomnolence, a broad presentation encompassing excessive daytime sleepiness, hypersomnia and sleep inertia, affects around 25 % of patients with a major depressive disorder. Yet, hypersomnolence is often overlook in clinical settings - which can prevent remission of the mood disorder in addition to significantly interfering with quality of life. Clinical guidelines are lacking to support clinicians in the diagnosis and treatment of hypersomnolence in depression. Pharmacological treatment with selective serotonin reuptake inhibitors is insufficient and noradrenaline and dopamine reuptake inhibitors or similar molecules are generally indicated. Low-sodium oxybate was recently approved for Idiopathic Hypersomnia, but studies are needed to assess its efficacy in patients with comorbid depression. In parallel, cognitive behavioral therapy for hypersomnia is being developed as adjunct non-pharmacological treatment. Light therapy might also be beneficial in these populations. This narrative review aims at proposing a diagnostic approach reconciliating psychiatry and sleep medicine nosologies, as well as offering a multimodal treatment algorithm for hypersomnolence in depression.

Identifiants

pubmed: 39423674
pii: S1389-9457(24)00474-X
doi: 10.1016/j.sleep.2024.10.008
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

462-470

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest Dr Moderie reports no biomedical financial interests or potential conflicts of interest. Dr Boivin provides conferences and legal expert advice on sleep-related topics.

Auteurs

Christophe Moderie (C)

Department of Psychiatry, McGill University, Montreal, Canada; Centre for Study and Treatment of Circadian Rhythms, Douglas Mental Health University Institute, McGill University, Montreal, Canada. Electronic address: christophe.moderie@mail.mcgill.ca.

Diane B Boivin (DB)

Department of Psychiatry, McGill University, Montreal, Canada; Centre for Study and Treatment of Circadian Rhythms, Douglas Mental Health University Institute, McGill University, Montreal, Canada.

Classifications MeSH